Independent Investment Research (IIR) has flagged that Parkway’s innovative tech for treatment of coal seam gas (CSG) brine could become best available technology (BAT) with a solid financial uptick for shareholders.

IIR has a risked base case valuation of $0.083 per share, a 10-fold increase on the current Parkway Corporate (ASX:PWN) price of $0.008/share, making it a potential 10-bagger, with further upside in an unrisked scenario.

IIR performed a detailed evaluation, and based on its own analysis of PWN found the company had disruptive, flexible, and low-cost tech, no competition at this stage and with strongly leverage earnings potential, in a growing market. Together with key personnel with skin in the game, the analyst noted great alignment between the company and shareholders.

ADDITIONAL RESOURCES

The IIR Report can be accessed by visiting:

https://investorhub.pwnps.com/activity-updates/new-pwn-research-report-26-june-2023

The Master Plan, which forms the basis for a large proportion of the valuation referenced in the IIR Report, can be accessed at:

https://investorhub.pwnps.com/announcements/4372527